NEW SITE — FASTER TURNAROUND, MORE LABS. READ ON

Vendor Intelligence Report: Lumira

Published 12 Nov 2026. 41-page investigative report on who is behind Lumira: corporate records, ownership, affiliate networks, and the vendor's lab-testing record. The first 4 pages are free to read on this page.

Researched and published by Finnrick Analytics. Reports draw on corporate records, affiliate-network analysis, and Finnrick's own laboratory testing record; vendors can challenge findings through the formal objections process at finnrick.com/vendor-support/objections.

Executive summary

Across 113 Finnrick lab tests, Lumira’s record is 67 pass / 45 fail, for an overall pass rate of 59%. The average hides a wide split: GHK-Cu is the cleanest line, Retatrutide is comparatively stronger but batch-sensitive, while NAD+ and BPC-157 sit in avoid-or-test-first territory. Ratings also become less forgiving under stricter grading, so Lumira is a per-product, exact-batch decision rather than a brand-average buy.

The most important quality-control signal is a primary-lab identity failure on a WL-series Retatrutide lot: the certificate says the sample contained a single compound that was not retatrutide, while Peptaura’s public registry did not surface that failure. The report separates that verified document from an unverified broader recall allegation, and from a separate passing third-party COA on another batch.

Lumira is not dormant: Peptaura shows a live, high-volume vendor page, broad catalog and escrow-style presentation. But the channel trail is fragmented. The direct Lumira store is unavailable; older Welon and PeptideCube routes are dead, parked or placeholder; and a newer Welon store names ABT Labs LLC while the operator’s formation and natural-person owner remain unresolved in the public record reviewed.

Commercial recourse is also a live issue. Peptaura emphasizes P2P and crypto payment rails, reviewed terms did not identify a legal entity or conventional chargeback path, and a code-driven X promotion network shows mixed disclosure. The practical read is directional, not binary: Lumira has defensible lines, but buyers need the lot-level and counterparty detail before relying on the catalog.

Inside the full report:

  • Per-product Finnrick pass/fail rates, rating trajectories and methodology-divergence charts for all 14 tested products
  • COA and registry crosswalk for the WL-series Retatrutide identity failure, a Verified/COA N/A batch and the Chromate Tirzepatide report
  • Domain and RDAP timeline across Lumira, Welon, PeptideCube, Allen and LiliPeptide infrastructure
  • ABT Labs LLC / Welon / Allen storefront-control map with unresolved Wyoming and Hong Kong registry leads
  • Affiliate-code, payment-rail and customer-recourse analysis, including X promoter disclosure examples

Risk assessment

  • Fail-heavy product lines risk — high: Lumira is comparatively stronger on GHK-Cu, Retatrutide and Tirzepatide, but NAD+, Wolverine, BPC-157, MOTS-c, TB-500 and Tesamorelin show weak or coin-flip Finnrick records.
  • Batch-verification and registry-integrity risk — high: ILS found Retatrutide lot WL-P00022 was not retatrutide; Peptaura returned Not Found for that lot and Verified / COA: N/A for WL-RT30-P00029.
  • Unresolved ownership and counterparty risk — high: UBO unresolved, Peptaura legal entity unnamed in reviewed terms, and ABT Labs LLC is named by storefronts but not registry-verified.
  • Brand-channel confusion risk — medium: Lumira direct store is unavailable, old Welon / PeptideCube routes are dead or parked, and no master official-channel / authorized-reseller list or anti-counterfeit program was found.
  • Affiliate-promotion risk — medium: X / web scan found multiple referral codes and mixed disclosure, including code drops without visible per-post disclosure.
  • Limited payment-recourse risk — medium: Peptaura emphasizes P2P and crypto rails, with no named acquirer / chargeback path and complaint evidence of store-credit or self-testing responses.